Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02834793
Registration number
NCT02834793
Ethics application status
Date submitted
13/07/2016
Date registered
15/07/2016
Date last updated
9/03/2022
Titles & IDs
Public title
Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome
Query!
Scientific title
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome
Query!
Secondary ID [1]
0
0
2014-002321-35
Query!
Secondary ID [2]
0
0
E2007-G000-338
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Lennox-Gastaut Syndrome (LGS)
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Epilepsy
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Other
0
0
0
0
Query!
Research that is not of generic health relevance and not applicable to specific health categories listed above
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Perampanel
Experimental: Perampanel up to 8 mg/day - During the Randomization Phase, participants will receive perampanel at a starting dose of 2 milligrams per day (mg/day). Thereafter, the dose will be increased to a maximum target dose of 8 mg/day according to individual tolerability and efficacy for up to 18 weeks. Participants who enter into Extension A will continue to receive perampanel at the dose last received during randomization phase. Participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion.
Participants who continue in Extension B will continue to receive perampanel at the dose last received at the end of Extension A.
Placebo Comparator: Matching placebo - During the Randomization Phase, participants will receive matching placebo for up to 18 weeks.
During the Extension A, participants who received placebo during the Randomization Phase will begin treatment with perampanel in a blinded manner in double-blind Conversion Period, starting at 2 mg/day and then up-titrated to a maximum target dose of 8 mg/day according to individual tolerability and efficacy. After the Conversion Period, participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion.
Treatment: Drugs: Placebo
Participants will receive matching placebo in Randomization phase.
Treatment: Drugs: Perampanel
Participants will receive perampanel in Randomization phase, open-label Extension A, and open-label Extension B.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Core Study Phase: Median Percent Change in Drop Seizure Frequency Per 28 Days During Double-blind Treatment Relative to the Prerandomization Phase (Baseline)
Query!
Assessment method [1]
0
0
Drop seizure was defined as a drop attack or spell involving the entire body, trunk, or head that led to a fall, injury, slumping in a chair, or the participant's head hitting a surface or that could have led to a fall or injury, depending on the participant's position at the time of the attack or spell. Seizure frequency was based on the number of drop seizures per 28 days, calculated as the number of drop seizures over the entire time interval divided by the number of days in the interval and multiplied by 28.
Query!
Timepoint [1]
0
0
Baseline up to 18 weeks
Query!
Secondary outcome [1]
0
0
Core Study Phase: Median Percent Change in Total Seizure Frequency Per 28 Days During Double-blind Treatment Relative to the Prerandomization Phase (Baseline)
Query!
Assessment method [1]
0
0
Total seizure was the number of seizures assessed and recorded by the participant's parent/caregiver in the participant seizure diary. Seizure diaries were used to collect seizure counts and types. Seizure frequency was based on the number of drop seizures per 28 days, calculated as the number of drop seizures over the entire time interval divided by the number of days in the interval and multiplied by 28.
Query!
Timepoint [1]
0
0
Baseline up to 18 weeks
Query!
Secondary outcome [2]
0
0
Core Study Phase: Percentage of Participants With 50% Response in the Maintenance Period of the Double-blind Treatment Phase Relative to the Prerandomization Phase (Baseline) for Drop Seizures
Query!
Assessment method [2]
0
0
Drop seizure was defined as a drop attack or spell involving the entire body, trunk, or head that led to a fall, injury, slumping in a chair, or the participant's head hitting a surface or that could have led to a fall or injury, depending on the participant's position at the time of the attack or spell. A responder was a participant who experienced a 50% or greater reduction in drop seizure frequency per 28 days during Maintenance from prerandomization.
Query!
Timepoint [2]
0
0
Baseline up to 18 weeks
Query!
Secondary outcome [3]
0
0
Core Study Phase: Percentage of Participants With 50% Response in the Maintenance Period of the Double-blind Treatment Phase Relative to the Prerandomization Phase (Baseline) for Total Seizures
Query!
Assessment method [3]
0
0
Total seizure was the number of seizures assessed and recorded by the participant's parent/caregiver in the participant seizure diary. Seizure diaries was used to collect seizure counts and types. A responder was a participant who experienced a 50% or greater reduction in drop seizure frequency per 28 days during Maintenance from prerandomization.
Query!
Timepoint [3]
0
0
Baseline up to 18 weeks
Query!
Secondary outcome [4]
0
0
Core Study Phase: Median Percent Change in Non-drop Seizure Frequency Per 28 Days During Double-blind Treatment Phase Relative to the Prerandomization Phase (Baseline)
Query!
Assessment method [4]
0
0
Non-drop seizures were defined as non-drop attacks or spells. Drop attacks and spells involved the entire body, trunk, or head and lead to a fall, injury, slumping in a chair, or the participant's head hitting a surface, or could lead to a fall or injury, depending on the participant's position at the time of the attack or spell. Seizure frequency was based on the number of drop seizures per 28 days, calculated as the number of drop seizures over the entire time interval divided by the number of days in the interval and multiplied by 28.
Query!
Timepoint [4]
0
0
Baseline up to 18 weeks
Query!
Secondary outcome [5]
0
0
Core Study Phase: Percentage of Participants With 75% Response in the Maintenance Period of the Double-blind Treatment Phase Relative to the Prerandomization Phase (Baseline) for Drop Seizures, Non-drop Seizures and Total Seizures
Query!
Assessment method [5]
0
0
Drop seizure was defined as a drop attack or spell involving the entire body, trunk, or head that led to a fall, injury, slumping in a chair, or the participant's head hitting a surface or that could have led to a fall or injury, depending on the participant's position at the time of the attack or spell. Non-drop seizures were defined as non-drop attacks or spells. Total seizure was the number of seizures assessed and recorded by the participant's parent/caregiver in the participant seizure diary. Seizure diaries were used to collect seizure counts and types. A responder was a participant who experienced a 75% or greater reduction in drop seizure/non-drop seizure/ frequency per 28 days during Maintenance from prerandomization.
Query!
Timepoint [5]
0
0
Baseline up to 18 weeks
Query!
Secondary outcome [6]
0
0
Core Study Phase: Percentage of Participants With 100% Response in the Maintenance Period of the Double-blind Treatment Phase Relative to the Prerandomization Phase (Baseline) for Drop Seizures, Non-drop Seizures and Total Seizures
Query!
Assessment method [6]
0
0
Drop seizure was defined as a drop attack or spell involving the entire body, trunk, or head that led to a fall, injury, slumping in a chair, or the participant's head hitting a surface or that could have led to a fall or injury, depending on the participant's position at the time of the attack or spell. Non-drop seizures were defined as non-drop attacks or spells. Total seizure was the number of seizures assessed and recorded by the participant's parent/caregiver in the participant seizure diary. Seizure diaries was used to collect seizure counts and types. A responder was a participant who experienced a 100% or greater reduction in drop seizure/non-drop seizure/ frequency per 28 days during Maintenance from prerandomization.
Query!
Timepoint [6]
0
0
Baseline up to 18 weeks
Query!
Secondary outcome [7]
0
0
Core Study Phase: Percentage of Participants With 50% Response in the Maintenance Period of the Double-blind Treatment Phase Relative to the Prerandomization Phase (Baseline) for Non-drop Seizures
Query!
Assessment method [7]
0
0
Non-drop seizures were defined as non-drop attacks or spells. Drop attacks and spells involved the entire body, trunk, or head and lead to a fall, injury, slumping in a chair, or the participant's head hitting a surface, or could lead to a fall or injury, depending on the participant's position at the time of the attack or spell. A responder was a participant who experienced a 50% or greater reduction in non-drop seizure frequency per 28 days during Maintenance from prerandomization.
Query!
Timepoint [7]
0
0
Baseline up to 18 weeks
Query!
Secondary outcome [8]
0
0
Core Study Phase: Percentage of Participants With Clinical Global Impression of Change Scores (CGIC) in the Double-blind Treatment Phase
Query!
Assessment method [8]
0
0
Assessment of disease severity utilized the CGIC scale at end of treatment to evaluate participants change in disease status from baseline. The CGIC is a 7-point likert scale that measures a physician's global impression of a participants clinical condition. Scale ranged from 1 to 7 with lower score indicated improvement (1=very much improved, 2=much improved, 3=minimally improved), higher score indicated worsening (5=minimally worse, 6= much worse, 7=very much worse), and a score of 4 indicated no change.
Query!
Timepoint [8]
0
0
Baseline up to 18 weeks
Query!
Secondary outcome [9]
0
0
Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [9]
0
0
A TEAE was defined as an adverse event with an onset date, or a worsening in severity from baseline (pre-treatment), on or after the first dose of study drug up to 28 days following study drug discontinuation. An AE was defined as any untoward medical occurrence in a participant or clinical investigation in a participant administered an investigational product. An AE does not necessarily have a causal relationship with a medicinal product. A serious adverse event (SAE) was defined as any AE if it resulted in death or life-threatening AE or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions or was a congenital anomaly/birth defect.
Query!
Timepoint [9]
0
0
From the date of the first administration of the study drug up to 28 days after the last dose of the study drug (up to 192 weeks)
Query!
Secondary outcome [10]
0
0
Number of Participants With Treatment-emergent Markedly Abnormal Laboratory Values
Query!
Assessment method [10]
0
0
Treatment-emergent markedly abnormal value for laboratory values was based Common Terminology Criteria for Adverse events (CTCAE) Version 4.0, and determined as if the post baseline CTCAE Version 4.0 grade increases from baseline and the post baseline grade was >=2 (>=3 for phosphate). Laboratory tests included: Hematology count with differential, Chemistry (Electrolytes, Liver function tests, Renal function parameters, Other: albumin, calcium, cholesterol, globulin, glucose, lactate dehydrogenase, phosphorus, total protein, lipid panel, uric acid), Urinalysis, and Viral tests (Hepatitis B surface antigen, Hepatitis C).
Query!
Timepoint [10]
0
0
From the date of the first administration of the study drug up to 28 days after the last dose of the study drug (up to 192 weeks)
Query!
Secondary outcome [11]
0
0
Number of Participants With Clinically Significant Vital Signs
Query!
Assessment method [11]
0
0
Clinically significant means that a value must have met both the criterion value and satisfied the magnitude of change relative to baseline. Vital sign parameters included systolic blood pressure (BP), diastolic BP, pulse rate.
Query!
Timepoint [11]
0
0
From the date of the first administration of the study drug up to 28 days after the last dose of the study drug (up to 192 weeks)
Query!
Secondary outcome [12]
0
0
Core Study Phase: Model Predicted Average Perampanel Concentrations at Steady State (Cav,ss) During the Maintenance Period of Core Study Phase
Query!
Assessment method [12]
0
0
Due to the early termination of the study resulting in reduced sample size and the variability in treatment response, population pharmacokinetic (PK) analysis and population pharmacokinetic/pharmacodynamic (PK/PD) modeling planned for this study were not conducted and hence data was not collected and analyzed for this outcome measure.
Query!
Timepoint [12]
0
0
Up to Week 18
Query!
Eligibility
Key inclusion criteria
- Participants must have a diagnosis of LGS as evidenced by:
1. more than one type of generalized seizure, including drop seizures (atonic,
tonic, or myoclonic) for at least 6 months before Visit 1;
2. an electroencephalogram (EEG) reporting diagnostic criteria for LGS at some point
in their history (abnormal background activity accompanied by slow, spike, and
wave pattern <2.5 hertz [Hz]).
- Participants must be at least 2 years old at the time of consent/assent
- Participants must have been <11 years old at the onset of LGS
- Participants must have experienced an average of at least 2 drop seizures per week in
the 4-week Baseline Period preceding randomization
- Participants must have been receiving 1 to 4 concomitant antiepileptic drugs (AEDs) at
a stable dose for at least 30 days before Visit 1 (vagal nerve stimulation (VNS) and
ketogenic diet do not count as AEDs). Use of cannabidiol (CBD) products is allowed and
is counted as one of the 4 maximum allowed concomitant AEDs. CBD dose and product must
have remained stable for at least 30 days before Visit 1 and is to remain the same
throughout the course of the Core Study
- In the investigator's opinion, parents or caregivers must be able to keep accurate
seizure diaries
- Body weight at least 8 kilogram (kg)
Query!
Minimum age
2
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Presence of progressive neurological disease
- Presence of drop seizure clusters where individual seizures cannot be reliably counted
(seizure clusters are defined as =2 drop seizures with <5 minutes between any 2
consecutive seizures)
- Prior treatment with perampanel with discontinuation due to safety issues (related to
perampanel)
- Prior treatment with perampanel within 30 days before Visit 1
- Evidence of clinically significant disease (eg, cardiac, respiratory,
gastrointestinal, renal disease, hepatic disease) that in the opinion of the
investigator(s) could affect the participant's safety or study conduct
- Scheduled for epilepsy-related surgery or any other form of surgery during the
projected course of the study
- Ketogenic diet and VNS, unless stable and ongoing for at least 30 days before Visit 1
- Treatment with an investigational drug or device within 30 days before Visit 1
- Status epilepticus within 12 weeks of Visit 1
- If felbamate is used as a concomitant AED, participants must be on felbamate for at
least 1 year, with a stable dose for 60 days before Visit 1. They must not have a
history of white blood cell (WBC) count below =2500/microliters (µL), platelets
<100,000/µL, liver function tests (LFTs) >3 times the upper limit of normal (ULN), or
other indication of hepatic or bone marrow dysfunction while receiving felbamate
- Concomitant use of vigabatrin: participants who took vigabatrin in the past must be
discontinued for at least 5 months before Visit 1, and must have documentation showing
no evidence of a vigabatrin-associated clinically significant abnormality in an
automated visual perimetry test
- Have had multiple drug allergies or a severe drug reaction to an AED(s), including
dermatological (eg, Stevens-Johnson syndrome), hematological, or organ toxicity
reactions
- Evidence of significant active hepatic disease. Stable elevations of liver enzymes,
alanine aminotransferase (ALT), and aspartate aminotransferase (AST) due to
concomitant medication(s) will be allowed if they are < 3 times the ULN
- Adrenocorticotropic hormone within the 6 months before Visit 1
- Had history of anoxic episodes requiring resuscitation within 6 months before Visit 1
- Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a
positive beta human chorionic gonadotropin [ß-hCG] with a minimum sensitivity of 25
International Units per Liter (IU/L) or equivalent units of ß-hCG or hCG). A separate
baseline assessment is required if a negative screening pregnancy test was obtained
more than 72 hours before the first dose of study drug.
- Females of childbearing potential who: a. had unprotected sexual intercourse within 30
days before study entry and who do not agree to use a highly effective method of
contraception (eg, total abstinence, an intrauterine device, a double-barrier method
[such as condom plus diaphragm with spermicide], a contraceptive implant, an oral
contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout
the entire study period or for 28 days after study drug discontinuation. Females using
hormonal contraceptives containing levogesterol must be on another form of
contraception as well. b. Are currently abstinent, and do not agree to use a
double-barrier method (as described above) or refrain from sexual activity during the
study period or for 28 days after study drug discontinuation. c. Are using hormonal
contraceptives but are not on a stable dose of the same hormonal contraceptive product
for at least 4 weeks before dosing and who do not agree to use the same contraceptive
during the study or for 28 days after study drug discontinuation. (NOTE: All females
will be considered to be of childbearing potential unless they are postmenopausal
[amenorrheic for at least 12 consecutive months, in the appropriate age group, and
without other known or suspected cause] or have been sterilized surgically [i.e.,
bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with
surgery at least 1 month before dosing])
- Had intermittent use of benzodiazepine of more than 4 single administrations in the
month before Visit 1
- A prolonged QT/QTc interval (QTc >450 milliseconds [ms]) as demonstrated by a repeated
electrocardiogram (ECG)
- Hypersensitivity to the study drug or any of the excipients
- Any history of a medical condition or a concomitant medical condition that in the
opinion of the investigator(s) would compromise the participant's ability to safely
complete the study
- Known to be human immunodeficiency virus (HIV) positive
- Active viral hepatitis (B or C) as demonstrated by positive serology at Screening
- Psychotic disorder(s) or unstable recurrent affective disorder(s) evident by use of
antipsychotics or prior suicide attempt(s) within approximately the last 2 years
- History of drug or alcohol dependency or abuse within approximately the last 2 years;
use of illegal recreational drugs
- Concomitant use of medications known to be inducers of cytochrome P450 (CYP3A)
including, but not limited to: rifampin, troglitazone, St. John's Wort, efavirenz,
nevirapine, glucocorticoids (other than topical usage), modafinil, pioglitazone, and
rifabutin
- Use of AEDs not recommended by Epilepsy Treatment Guidelines for use in LGS including,
but not limited to carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin,
tiagabine, and vigabatrin
- Any suicidal ideation with intent with or without a plan within 6 months before Visit
2 (that is, answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of
the Columbia Suicide Severity Rating Scale (C -SSRS) in participants aged 8 and above.
- Participants with rare hereditary problems of galactose intolerance, the Lapp lactase
deficiency or glucose-galactose malabsorption.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/12/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
19/07/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
101
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Query!
Recruitment hospital [1]
0
0
Queensland Children's Hospital - South Brisbane
Query!
Recruitment hospital [2]
0
0
Austin Health - Heidelberg
Query!
Recruitment hospital [3]
0
0
Royal Brisbane & Women's Hospital - Brisbane
Query!
Recruitment hospital [4]
0
0
Royal Melbourne Hospital - Melbourne
Query!
Recruitment hospital [5]
0
0
St Vincent's Hospital Melbourne - Melbourne
Query!
Recruitment hospital [6]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [2]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [3]
0
0
- Brisbane
Query!
Recruitment postcode(s) [4]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Idaho
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Michigan
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Minnesota
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Jersey
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Ohio
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Pennsylvania
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Utah
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Virginia
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Washington
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Wisconsin
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Brussels
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Hainaut
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Bruxelles
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Jette
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Ottignies-Louvain-la-Neuve
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Poruba
Query!
Country [25]
0
0
Czechia
Query!
State/province [25]
0
0
Praha
Query!
Country [26]
0
0
India
Query!
State/province [26]
0
0
Gujarat
Query!
Country [27]
0
0
India
Query!
State/province [27]
0
0
Karnataka
Query!
Country [28]
0
0
India
Query!
State/province [28]
0
0
Kerala
Query!
Country [29]
0
0
India
Query!
State/province [29]
0
0
Maharashtra
Query!
Country [30]
0
0
India
Query!
State/province [30]
0
0
Hyderabad
Query!
Country [31]
0
0
India
Query!
State/province [31]
0
0
New Delhi
Query!
Country [32]
0
0
Japan
Query!
State/province [32]
0
0
Fukuoka
Query!
Country [33]
0
0
Japan
Query!
State/province [33]
0
0
Hakodate
Query!
Country [34]
0
0
Japan
Query!
State/province [34]
0
0
Kagoshima-city
Query!
Country [35]
0
0
Japan
Query!
State/province [35]
0
0
Niigata
Query!
Country [36]
0
0
Japan
Query!
State/province [36]
0
0
Osaka
Query!
Country [37]
0
0
Japan
Query!
State/province [37]
0
0
Sapporo
Query!
Country [38]
0
0
Japan
Query!
State/province [38]
0
0
Shizuoka
Query!
Country [39]
0
0
Korea, Republic of
Query!
State/province [39]
0
0
Daegu
Query!
Country [40]
0
0
Korea, Republic of
Query!
State/province [40]
0
0
Seoul
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eisai Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is being conducted to demonstrate that perampanel given as adjunctive
anti-epileptic treatment is superior to placebo in reducing the number of drop seizures in
participants with inadequately controlled seizures associated with Lennox-Gastaut Syndrome
(LGS).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02834793
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02834793
Download to PDF